Palvella Therapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 3 days.
- Recent price momentum is +28.1% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 18.1% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2849 U.S. stocks StockVane covers.
Last computed: 2026-11-21 14:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability F
How much profit the business keeps from each dollar of sales and capital.
| Return on equity | -92.1% | Better than 6% |
| Return on invested capital | -83.8% | Better than 3% |
Momentum A-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 0.6% | Better than 75% |
| 6-month return | 25.3% | Better than 87% |
| 12-month return (ex latest month) | 34.3% | Better than 73% |
| Distance below 52-week high | 20.6% | Better than 59% |
Financial Health A-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 5.2x | Better than 87% |
| Debt to assets | 1.1% | Better than 92% |
| Interest coverage | -6.2x | Better than 16% |
Analyst View A-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 59.4% | Better than 72% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 145.77
- Open
- 143.10
- Day range
- 142.22 - 148.69
- Avg price
- 145.05
- Volume
- 192.67K
- Turnover
- 27.95M
- Turnover ratei
- 1.75%
- Volume ratioi
- 0.93
- Amplitudei
- 4.44%
- 52-week rangei
- 72.23 - 179.95
Valuation
- P/Ei
- -38.50
- P/E (TTM)i
- -25.83
- P/Bi
- 10.55
- EPSi
- -3.71
- Book value / shi
- 13.54
- Net profit
- -54.23M
- Net assets
- 197.92M
Share structure
- Market cap
- 2.09B
- Float capi
- 1.57B
- Shares out
- 14.62M
- Float sharesi
- 11.01M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
20.6% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+3.85M net over the window
Short interest
- Shares short
- 2.60M
- % of floati
- 18.06%
- Days to coveri
- 11.46
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Palvella Therapeutics (PVLA)?
Palvella Therapeutics last traded at 142.85. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Palvella Therapeutics's market cap?
About 2.09B.
What is the P/E ratio of Palvella Therapeutics?
The trailing twelve-month P/E is -25.83. The Valuation tab shows it against the stock's own five-year range.
Does Palvella Therapeutics pay a dividend?
Palvella Therapeutics does not currently pay a regular dividend.
Is Palvella Therapeutics a buy according to analysts?
The consensus of 12 analysts is a Buy rating, with an average 12-month price target of 227.73, which implies 59.4% upside from the current price. This is not investment advice.
What is Palvella Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Palvella Therapeutics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Palvella Therapeutics discussion 0 comments